Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abraxis BioScience has reported positive Phase I trial data, which shows clinical benefit of Abraxane for injectable suspension in combination with Gemzar in advanced pancreatic patients.
Subscribe to our email newsletter
Of the original 20 patients enrolled at the nab-paclitaxel 100mg/m2 dose, 17 had levels of CA 19-9 that could be evaluated. CA 19-9 levels dropped more than 20% in 82% of patients, according to the researchers. Reductions in CA 19-9 of more than 70% were observed in 64% of patients. Utilizing CAT scan criteria, nine of the 16 patients (56%) who had serial scans had partial responses. Twelve of the 16 patients (75%) had partial responses or stable disease for more than four months.
Sparc (secreted protein acidic and rich in cysteine) data were available in 12 patients for which response data were available. Six of eight (75%) Sparc positive patients responded to treatment while only one of four (25%) Sparc negative patients responded to treatment.
Based on these results, Abraxis plans to conduct additional studies to evaluate the safety and efficacy of Abraxane in patients with first and second-line pancreatic cancer.